01 December 2004
Immunogenicity of hepatitis B vaccine in multi-transfused thalassemic patients with and without hepatitis C infection: A comparative study with healthy controls
Hossein Froutan-Pishbijari, Hadi Ghofrani, Shahram Mirmomen, Siamak Kazemi -Asl, Mohsen Nassiri-Toosi, Mohammad-Jafar Farahvash, Hossein Hashemi Toroghi, Keyvan Aminian, Fariborz Mansour-Ghanaei, Amir-Hossein BagherzadehMed Sci Monit 2004; 10(12): CR679-683 :: ID: 13235
Abstract
Background:Hepatitis C virus (HCV) infection is highly prevalent in thalassemic patients. This may decrease serum antibody response to hepatitis B virus (HBV) vaccine. There is also some alteration in the immune system of multi-transfused thalassemic patients as a consequence of iron overload. We deduced that HCV infection may reduce the effectiveness of HBV vaccine in multi-transfused thalassemic patients.Material/Methods:Subjects were cited and studied prospectively in three groups. Group 1:125 multi-transfused thalassemic patients with negative serum HCV antibody, Group 2:96 multi-transfused thalassemic patients with positive serum HCV antibody on at least 2 different occasions, and Group3:100 healthy subjects. Subjects in all groups had negative serum HBsAg, anti-HBc, and anti-HBs, and they received three 20-µg doses of recombinant HBV vaccine in months 0,1, and 6. The anti-HBs titer was obtained one month after the last dose of vaccine and was considered seroprotective if ł10 IU/l.Results:The seroprotection rate was 83.2% in Group 1 and 80.2% in Group 2 (P=0.74). It was 86% in healthy subjects, which didn’t significantly differ from HCV-positive and -negative thalassemics (P=0.56). Moreover, the mean values of ALT among the responder and non-responder thalassemic patients were 55.5±41.9 and 57.4±48.5 U/l, respectively (p=0.802). During the vaccination periods, patients in all 3 groups did not show any significant adverse reactions.Conclusions:Our study shows that three standard doses of HBV vaccine are immunogenic and safe in multi-transfused thalassemic patients with or without HCV infection.
Keywords: Hepatitis B Vaccines - adverse effects, Hepatitis C Antibodies - administration & dosage, Thalassemia - complications, Thalassemia - immunology, Adolescent, Blood Transfusion, Child, Cohort Studies, Hepatitis Antibodies - blood, Hepatitis B - prevention & control, Hepatitis B Antibodies - blood, Hepatitis B Vaccines - therapeutic use, Hepatitis B virus - immunology, Hepatitis C - complications, Hepatitis C Antibodies - blood, Immunization Schedule, Thalassemia - immunology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952